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Background
Malignant thoracic tumor is a disease with high incidence and mortal-
ity, and incidence is expected to continue to rise in future. Surgery is 
the ﬁrst choice of therapy, but is not indicated in many cases. While 
systemic chemo- and radiotherapy have been used for unresectable ma-
lignant thoracic tumors, satisfactory results are not usually obtained. A 
great need currently exists for the establishment of effective treatments 
for unresectable malignant thoracic tumors. Radiofrequency (RF) abla-
tion has been examined as an effective minimally invasive treatment 
for many neoplasms, including malignant liver tumors, and has been 
used in recent years to treat bone, kidney, adrenal gland, thyroid gland, 
breast and brain neoplasms. Several experimental studies have reported 
that RF ablation is highly effective, because lung tumors are surround-
ed by normal pulmonary parenchyma, resulting in the so-called “oven 
effect”. Ever since the study by Dupuy et al. [1], several studies have 
investigated short, middle, and long-term results for RF ablation in the 
treatment of lung tumors [2-4]. The present study retrospectively inves-
tigated mid-term technique effectiveness of malignant thoracic tumors 
after RF ablation in our institute. We focused on the relations between 
technical effectiveness and tumor size, and ground-glass attenuation 
(GGA) appears around a tumor during or immediately after RF abla-
tion. We also reviewed complications related to lung RF ablation.
Materials and Methods
Between June 2001 and March 2007, CT-guided RF ablation was per-
formed on 834 malignant lung tumors of 304 patients in our institute. 
In this presentation we reviewed our patients between June 2001 and 
January 2006. Patients for whom periodical follow-up CT was not 
performed after RF ablation were excluded from the present study. As a 
result, we retrospectively investigated 461 tumors in 169 patients (109 
men and 60 women) who underwent periodical follow-up CT after RF 
ablation.
Mean patient age at the time of ﬁrst RF ablation was 63.2 years (range, 
24-88 years). Tumors comprised primary lung cancer in 32 patients (34 
tumors), and lung metastases in 137 patients (427 tumors). Surgery was 
not indicated in any case ( unresectable due to other diseases, refusal to 
undergo surgery, or advanced cancer,). All primary lung tumors were 
non-small cell carcinomas. Metastatic disease was from colon cancer (n 
= 154), lung cancer (n = 76), renal cell carcinoma (n = 67), hepatocel-
lular carcinoma (n = 31), urachal cancer (n = 23), uterine leiomyosar-
coma (n = 19), adenoid cystic carcinoma (n = 15), esophageal cancer (n 
= 11), adrenal cancer (n = 10), synovial sarcoma (n = 9), ureteral cancer 
(n = 8) and others (n = 38).
In all cases, percutaneous RF ablation was performed under CT ﬂuo-
loscopy guidance while monitoring vital signs and continuous pulse 
oximetry. As a general rule, 0.1-0.3 mg of fentanyl citrate was used as 
an analgesic, and RF ablation was performed under local anesthesia 
using lidocaine . As necessary, epidural anesthesia was administered by 
percutaneously injecting 5-10 ml of 2% lidocaine and 1 ml of fentanyl 
through an epidural tube.
In 214 tumors, a Cool-tip electrode and a generator (CC-1; Radionics, 
Burlington, USA) were used. In 244 tumors, a LeVeen electrode and 
generator (RF2000/3000; Boston Scientiﬁc, Natic, USA) were used. 
With the Radionics RF ablation machine, cold physiological saline was 
circulated within the lumen of the puncture electrode, and RF ablation 
was performed for 12 min. Immediately after RF ablation, tempera-
ture of the electrode tip placed at the tumor was measured. Ablation 
was completed if temperature was ≥60 ˚C. If temperature was <60 ˚C, 
ablation was performed again. With the Boston Scientiﬁc RF ablation 
machine, ablation was performed until impedance drastically increased. 
As a general rule, each area was cauterized twice. If a tumor was too 
large to be ablated in a single session, the electrode was re-inserted as 
needed until ablation volume exceeded tumor volume as assessed on 
CT [20].
Follow-up CT study was conducted immediately after, 1-2 months, 4-6 
months and 9-12 months after RF ablation, then every 6 months there-
after. When not contraindicated, contrast-enhanced CT was performed 
at the same time.
When examined by CT, ground-glass attenuation (GGA) appears 
around a tumor during or immediately after RF ablation. Based on the 
notion that GGA is equivalent to heat-damaged pulmonary parenchyma 
including the tumor, each ablation was performed to maximize GGA 
until ablation volume exceeded tumor volume as assessed on CT. A 
review of CT ﬁndings showed that GGA varied widely. We classiﬁed 
them into complete or incomplete-type when we reviewed them.
Results
Technical success: A total of 253 sessions were performed on the 169 
patients to treat the 461 tumors. All sessions were completed without 
procedure-related severe complication or death.
Local progression: During the assessment period, local progression did 
not occur in 369 of the 461 tumors (80.0%). Overall 1-, 2- and 3-year 
primary technique effectiveness rates as assessed by Kaplan-Meier 
methods were 72.3%, 59.5% and 53.0%, respectively. On the other 
hand, local progression occurred in 92 tumors (20.0%) during the same 
period. Re-RF ablation was performed on 41 tumors (44.6%). Re-RF 
ablation was performed once on 35 tumors, twice on 5 tumors and three 
times on 1 tumor. During the assessment period, secondary technique 
effectiveness rate was 86.6% (399 of the 461 tumors). Overall 1-, 2- 
and 3-year secondary technique effectiveness rates were 82.1%, 70.5% 
and 63.8%, respectively.
In relation to tumor size, local progression did not occur during the 
assessment period in 300 of the 355 tumors ≤2 cm (84.5%), 39 of the 
63 tumors 2-3 cm (69.8%) and 30 of the 43 tumors >3 cm (69.8%). The 
1-, 2- and 3-year technique effectiveness rates for each tumor size as 
determined by Kaplan-Meier methods were as follows: ≤2 cm tumors, 
78.4%, 65.6% and 57.6%, respectively; 2-3 cm tumors, 50.0%, 33.7% 
and not assessed (because of small number) , respectively; and >3 cm 
tumors, 53.1%, 44.3% and not assessed (because of small number), 
respectively. 
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In relation to GGA type, local progression did not occur during the 
assessment period in 292 of the 341 complete-type tumors (85.6%) or 
72 of the 115 incomplete-type tumors (62.6%). The 1-, 2- and 3-year 
technique effectiveness rates as assessed by Kaplan-Meier methods 
were 77.7%, 64.8% and 60.5% for complete-type tumors and 57.8%, 
45.3% and 33.9% for incomplete-type tumors, respectively. Tumor size 
for incomplete-type group was signiﬁcantly larger than for complete 
type. (p<0.05)
Complications: The incidence of pneumothorax, pleural effusion, 
and tube placement of pneumothorax were 52.2%, 18.8%, and 20.5% 
respectively. Two patients died during the course of the study because 
of intractable pneumothorax and massive hemoptysis.
Discussion
In the present study, a signiﬁcant difference was noted between ≤2 cm 
and >2 cm tumors, but not between 2-3 cm and >3 cm tumors. Mid-
term technique effectiveness was favorable for ≤2 cm tumors. This may 
be attributable to the ablation capacity of RF systems. Since we often 
used a system with the range of ablation of a 1-3-cm sphere, complete 
ablation could be expected with tumors ≤2 cm in size. We now use 
larger LeVeen needles to overcome this problem.
Based on this report, we deﬁned complete necrosis as having a safety 
margin of ≥5 mm, and technique effectiveness rates were more favor-
able for complete-GGA-type tumors. Surrounding GGA can be as-
sessed immediately after RF ablation, and may be useable as an indica-
tor of technique effectiveness. However, local progression still occurred 
with tumors completely surrounded by GGA, so not all GGA reﬂects 
coagulative necrosis. Reasons for this include the following: degree of 
ablation cannot be assessed in areas adjacent to existing structures such 
as the pleura and/or large pulmonary vessels; GGA could be caused 
by other factors such as bleeding; and the discrepancy between range 
of GGA seen on CT and actual histopathological range of necrosis. As 
complete-type tumors were smaller than incomplete-type tumors with 
statistical signiﬁcance, GGA type can simply reﬂect tumor size.
Our study revealed that secondary technique effectiveness rates 
improved with re-RF ablation in the treatment of local progressions. 
Compared to other treatments such as surgery and radiotherapy, RF 
ablation is advantageous because therapy is easily repeated many times.
RF ablation appears to be a safe and minimally invasive option with 
negligible mortality and little morbidity in selected patients with unre-
sectable thoracic malignant tumors.
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In the last decades, thanks to the introduction of various ancillary diag-
nostic and therapeutic techniques, the role of bronchoscopy has evolved 
as an essential tool in the management of lung cancer in any step of the 
natural history of the disease.
From the early detection (autoﬂuorescence bronchoscopy) to the 
diagnosis and staging (transbronchial needle aspiration, ultrasound 
bronchoscopy), the value of bronchoscopy as a diagnostic and staging 
method is worldwide acknowledged. On the contrary, the potential 
therapeutic role of bronchoscopy in lung cancer is still underrated and 
in the ﬂow-charts of treatment modalities of lung cancer the interven-
tional pulmonology procedures are often unmentioned.
50-60% of lung cancers occurs in central airways and thus are reach-
able by bronchoscopic techniques that can be utilised with curative 
intent or for palliative care. 
Various intraluminal bronchoscopic treatment methods have been 
used with curative intent in early stage cancer of the central airways 
(carcinoma in situ or microinvasive carcinoma). Photodynamic therapy 
(PDT), endobronchial brachyterapy, laser therapy, electrocautery and 
cryotherapy have been employed in this ﬁeld. Complete response rate 
ranges from 75 to 97 % and it is higher when the tumor has a limited 
surface area less than 1 square centimeter. 
More frequently, bronchoscopic techniques are used with palliative 
intent in cases of malignant central airways obstruction in patients not 
candidate for surgery. Symptoms such as dyspnea, cough, post-obstruc-
tive pneumonia and haemoptysis are commonly present in patients with 
lung cancer and may be related to the endobronchial extension of the 
tumor. These symptoms may be life-treathening and cause of death or 
may affect the quality of life. 
There are various bronchoscopic techniques to be employed in the 
palliative treatment of endobronchial tumours. The choice depends on 
three major factors: 
1) the need to obtain an immediate effect for symptoms relief in 
patients with severe dyspnoea and imminent respiratory failure or 
life-threatening haemoptysis. Therapeutic bronchoscopy using laser, 
elctrocauthery, argon plasma coagulation and the use of stents may 
provide an immediate reopening of the airway lumen. 
2) the type of stenosis that can be related to endoluminal growing 
tumours, to extrinsic compression or to mixed pattern with intralu-
minal tissue associated with intramural spread or extrinsic compres-
sion; 
3) the local availability of facilities or experience.
In selected cases, the bronchoscopic treatment of lung cancer can 
provide faster relief of symptoms than any other treatment measure. 
Unfortunately, the endoscopic intervention is generally reserved to 
œadvanced cases”, after that oncologic treatment as chemo- or radio-
therapy have failed. On the contrary, the above mentioned procedures 
should be considered means of treatment for central airways tumours, 
that do not compete but must be integrated with other care modalities, 
even at the beginning of the therapeutical management of the patient. 
In this sense a close cooperation between the interventional pulmo-
nologist, the oncologist and the radiotherapist is an essential step to 
optimise the management of lung cancer patient.
The different techniques for disobstructing airways in patients affected 
by lung cancer will be discussed in this “Meet the Professor” Session.
